Fast triage of chest pain patients

ADVIA Centaur High-Sensitivity Troponin I Assay

The ADVIA Centaur® High-Sensitivity Troponin I (TNIH) assay* is the latest addition to Siemens Healthineers’ comprehensive cardiac menu to assist clinicians with the diagnosis and treatment of chest pain patients. Designed to aid in diagnosing acute myocardial infarctions (AMI) through the quantitative measurement of cardiac troponin I in serum or plasma, high-sensitivity troponin plays a critical role in the timely diagnosis of AMI, or heart attacks.

ADVIA Centaur High-Sensitivity Troponin I assay – Accurate results you can...
ADVIA Centaur High-Sensitivity Troponin I assay – Accurate results you can trust for fast triage of chest pain patients.
Source: Siemens Healthineers
The ADVIA Centaur High-Sensitivity Troponin I assay.
The ADVIA Centaur High-Sensitivity Troponin I assay.
Source: Siemens Healthineers

The ADVIA Centaur® High-Sensitivity Troponin I (TNIH) assay* is the latest addition to Siemens Healthineers’ comprehensive cardiac menu to assist clinicians with the diagnosis and treatment of chest pain patients. Designed to aid in diagnosing acute myocardial infarctions (AMI) through the quantitative measurement of cardiac troponin I in serum or plasma, high-sensitivity troponin plays a critical role in the timely diagnosis of AMI, or heart attacks.

The ADVIA Centaur® High-Sensitivity Troponin I assay is a true high-sensitivity assay:

  • Offers improved cardiac patient care with a high-sensitivity troponin assay that meets current European Society of Cardiology clinical guidelines
  • Provides fast, accurate and actionable test results allow clinicians to confidently rule in/rule out a myocardial infarction when triaging patients with chest pain
  • Ensures reliable results from a proven, trusted technology coupled with three new monoclonal antibodies

Compared to traditional troponin assays, the Siemens Healthineers ADVIA Centaur TNIH assay is able to detect lower levels of troponin and smaller changes to a patient’s troponin levels, which may be an early indication of AMI. This design affords clinicians greater confidence in patient results at the low end of the assay range by delivering precision that provides the ability to measure slight, yet critical, changes between serial troponin I values.

Precision at the low end is important to minimize analytic variation that could confuse a clinician’s assessment of a clinically significant change. With this data in hand, clinicians have the ability to more quickly diagnose and treat patients with suspected AMI, in some cases in as little as one to three hours.

Click here to learn more

*Not available for sale in the U.S.

 

Source: Siemens Healthineers

01.07.2017

Related articles

Cardiology

Breast implants may impede ECG and lead to false heart attack diagnosis

Breast implants may impede an electrocardiogram (ECG) and could result in a false heart attack diagnosis, according to research by the European Heart Rhythm Association (EHRA), a registered branch of…

Plaques

Identifying a likely heart attack

UK researchers have identified a new approach, which could make it easier to identify fatty plaques that could cause heart attacks or a stroke.

Cardiology I

Chest pain units in Germany

The German care system for patients with acute and unspecific chest pain is unique in Europe. The closely knit and countrywide network of accredited Chest Pain Units (CPUs) ensures fast and targeted…

Related products

Magnetic Resonance Imaging - Accessories / Complementary Systems

allMRI GmbH - Stretcher

allMRI GmbH

Infectious diseases testing

Atlas Genetics - Atlas Genetics io system

Atlas Genetics Ltd

Immunochemistry

Beckman Coulter - Access AccuTnI+3 Troponin I Assay

Beckmann Coulter, Inc.

Immunochemistry

Beckman Coulter - Anti-Mullerian Hormone (AMH)

Beckmann Coulter, Inc.

Clinical chemistry

Biomed – Cystatin C Turbidimetric Assay

Biomed Labordiagnostik GmbH